Navigation Links
Mindray Announces First Quarter 2009 Financial Results
Date:5/11/2009

SHENZHEN, China, May 11 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide announced today its selected unaudited financial results for the first quarter ended March 31, 2009.

    Highlights for First Quarter 2009
    -- First quarter 2009 net revenues were $134.2 million, an increase of
       53.5% over the first quarter of 2008
    -- Non-GAAP operating income in the first quarter 2009 was $34.7 million,
       a 12.6% increase from the first quarter of 2008. First quarter 2009
       GAAP operating income was $29.4 million
    -- Accutorr V -- first jointly developed product by Mahwah and Shenzhen
       teams was successfully released to the market.

"Despite weaker-than-expected market trends in US and Europe, we are pleased to report a relatively strong quarter," commented Mr. Xu Hang, Mindray's chairman and co-chief executive officer. "During the quarter, Mindray responded quickly to the challenging market dynamics and initiated measures to effectively control product costs and reduce operating expenses to sustain operating profit growth. We are confident that Mindray will continue to outperform the market in the remainder of 2009 and beyond, as a result of the strength of our highly competitive operating structure which enables us to deliver products that meet the quality, performance and price requirements of our growing global customer base."


                               SUMMARY - 1st Quarter 2009


(in $ millions, except per-share 1Q/2009 1Q/2008 % change

data)

    Net Revenues                           134.2       87.4            53.5%
           Revenues generated in China      62.4       42.8            45.8%
      Reve
'/>"/>
SOURCE Mindray Medical International Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Mindray Files Annual Report on Form 20-F with U.S. Securities and Exchange Commission
2. Mindray to Report First Quarter 2009 Financial Results on May 11, 2009
3. Mindray Medical to Exhibit New Products at 61st China International Medical Equipment Fair
4. Mindray Announces Option Exchange Offer
5. Mindray to Report Fourth Quarter and Fiscal Year 2008 Financial Results on March 4, 2009
6. Mindray Medical Achieves 2008 Product Development Goals and Announces Strong Pipeline for 2009
7. Mindray Announces Preliminary 2008 Operating Results
8. Mindray Medical to Present at the 27th Annual J.P. Morgan Healthcare Conference
9. Mindray Medical to Exhibit at RSNA 2008 in Chicago, from November 30th to December 4th, 2008
10. Mindray Announces 2008 Third Quarter and Nine Months Results
11. Mindray to Report Third Quarter 2008 Financial Results on November 11, 2008

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)....24/PRNewswire-FirstCall/--CenteneCorporation(NYSE...edicaidhasselectedCenteneasoneoftwoCoordinatedCare...tedAccessNetwork(MississippiCAN),acoordinatedcarep...sworkingwiththeDivisiontoexecuteacontractinwhichth...,asMagnoliaHealthPlan(Magnolia). ,, BasedinJack...
(Date:11/24/2009)...ose choking hazard, are too loud, or contain dange...lthDay News) -- As the holiday shopping season beg... are still being sold in stores across the United ...ual Trouble in Toyland report, released Tuesday ... , The report focuses on toys that pose a choki...
(Date:11/24/2009)...tes didn,t differ greatly between high- and low-vo...ov. 24 (HealthDay News) -- Do hospitals that condu...best results for patients? Maybe not. , Prior r..." when it comes to artery-opening procedures, but ...ow- and high-volume hospitals performing more or l...
(Date:11/24/2009)...archers have found that hormones produced during p...he growth of breast cancer. This protein, alpha-fe...ated agent for the treatment and prevention of bre...ncer Prevention Research , a journal of the Americ... in pregnancy, such as estrogen, all induce AFP, w...
(Date:11/24/2009)...ample, study finds no added use but higher costs ,...Direct-to-consumer drug ads may contribute to high...xamined sales of the widely used antiplatelet drug...rom 1999 to 2005 for 27 state Medicaid programs fo...ogrel did not increase people,s use of the drug bu...
Breaking Medicine News(10 mins):Health News:Centene Corporation Receives Notification of Intent to Contract From the State of Mississippi 2Health News:Dangerous Toys Still on Store Shelves, Report Finds 2Health News:Dangerous Toys Still on Store Shelves, Report Finds 3Health News:Angioplasty Outcomes May Vary Little Between Hospitals 2Health News:Angioplasty Outcomes May Vary Little Between Hospitals 3Health News:Protein from pregnancy hormone may prevent breast cancer 2Health News:Advertising to Consumers May Raise Drug Prices 2
...d anti-HLA antibody assays both contribute to ...g weaned off immunosuppr...Cylex in,conjunction with the University of Pittsb... antibody assays may be independent,measures of di...
... New evidence for the first time suggests that peo...ill over time experience a progressive worsening o...w long they have the disorder, according to a new ...100 patients (50 with short-term rhinitis, and 50 ...
...ing cause of death for female survivors; cardiovas...31 (HealthDay News) -- People who survived Hodgkin...veloping and dying from another cancer or cardiova...s, according to the researchers. , "The bottom-li...
...es demonstrated potential for pazopanib as a singl...ung cancer and advanced,renal cell cancer:, -- ...ancer, 86 percent of patients who received pa...rate of 35 percent. The median duration of respons...
...medication use in young children has been linked t...ral deaths, leading the FDA to recommend against t...pite these concerns about safety and efficacy, the...( www.emnet-usa.org ) led by Katherine ODonnell, M...
...s would offer help to millions of diabetics who ar...s) -- Better screening and diagnosis for diabetes ...ans who don,t realize they have the disease, a new... Hopkins School of Medicine in Baltimore, said in ...
Other Medicine News:Health News:Cell-Mediated Immunity and Anti-HLA Antibody Tests Provide Insight to Immune Response in Renal Transplant Patients 2Health News:Cell-Mediated Immunity and Anti-HLA Antibody Tests Provide Insight to Immune Response in Renal Transplant Patients 3Health News:Hodgkin Lymphoma Kids Face Greater Risk of Future Problems 2Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 2Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 3Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 4Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 5Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 6Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 7Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 8Health News:Study examines cold medication use in young children 2Health News:Panel Calls for Better Diabetes Screening 2
(Date:11/23/2009).../--HealthWarehouse.com,Inc.(OTCBulletinBoard:HEWA)...nancialresultsforthethirdquarterendedSeptember30,2...,drivenbyheavygrowthinprescriptionsalesandpharmacy...to34.6%andthenetlossforthequarterwas$619,114compar...ber30,2008. ,, "Wecontinuetoseeconsumerstransfe...
(Date:11/23/2009)...ll/--BostonScientificCorporation(NYSE: BSX )issche...rence,December1-2. ,, RayElliott,PresidentandCh...ntandChiefFinancialOfficer,willparticipateina30-mi...,beginningatapproximately9:00a.m.E.T. ,, Alivew...edpartiesatBostonScientific,swebsiteat www.bostons...
(Date:11/23/2009)...FirstCall/--BeckmanCoulter,Inc.(NYSE: BEC ),aleadi...simplify,automate,andinnovatecomplexbiomedicaltest...vicepresidentofstrategy,willpresentatthePiperJaffr...12:00p.m.(ET). ,, (Logo: http://www.newscom.com...astofBeckmanCoulter,spresentationcanbeaccessedbyvi...
Breaking Medicine Technology:HealthWarehouse.com, Inc. Announces Third Quarter Financial Results; Revenues, Margins, and Orders Shipped Increase Over Third Quarter 2008 2HealthWarehouse.com, Inc. Announces Third Quarter Financial Results; Revenues, Margins, and Orders Shipped Increase Over Third Quarter 2008 3Hypertronics Circular HyperGrip 28R 29 Connectors Selected for Biosense Websters CARTO 28R 29 3 Navigation System 54663 1Hypertronics Circular HyperGrip 28R 29 Connectors Selected for Biosense Websters CARTO 28R 29 3 Navigation System 54663 2Trust for Americas Health Praises Major Foundations for Supporting Prevention as a Central Part of Health Reform 54661 1Trust for Americas Health Praises Major Foundations for Supporting Prevention as a Central Part of Health Reform 54661 2Study shows how to boost value of Alzheimers fighting compounds 54660 1Study shows how to boost value of Alzheimers fighting compounds 54660 2
...hown to Be Safe and Effective for Menopausal ..., Fla., Oct. 3 A study presented today,at the 200...ociety (NAMS),revealed that Divigel(R) (estradiol ...severity of moderate to severe hot flashes associa...he meeting found that Divigel(R),is a safe and wel...
...Systems Incorporated,(Nasdaq: IMCL ) and Bristol-...,that the U.S. Food and Drug Administration (FDA) ...b) product labeling to include overall survival,da...hibitor,(EGFR)-expressing metastatic colorectal ca...can- and oxaliplatin-based regimens. The approval...
Other Medicine Technology:New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes 2Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 2Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 3Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 4Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 5Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 6Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 7
Kerrison style punch
Aaron 2250 Electrosurgery Generator
Sabre 2400 Electrosurgery Generator, 240V, 50Hz
ExcaliburPlus PC Electrosurgery Generator, 100V, 50Hz/60Hz
Medicine Products: